PMC/PubMed Indexed Articles
Indexed In
- Open J Gate
- Genamics JournalSeek
- JournalTOCs
- Ulrich's Periodicals Directory
- RefSeek
- Hamdard University
- EBSCO A-Z
- OCLC- WorldCat
- Publons
- Geneva Foundation for Medical Education and Research
- Euro Pub
- Google Scholar
Useful Links
Share This Page
Journal Flyer
Open Access Journals
- Agri and Aquaculture
- Biochemistry
- Bioinformatics & Systems Biology
- Business & Management
- Chemistry
- Clinical Sciences
- Engineering
- Food & Nutrition
- General Science
- Genetics & Molecular Biology
- Immunology & Microbiology
- Medical Sciences
- Neuroscience & Psychology
- Nursing & Health Care
- Pharmaceutical Sciences
Shojiro Kikuchi
Department of Surgery, Institute for Advanced Medical Science, Hyogo College of Medicine, Nishinomiy, Japan
Biography
Dr. Shojiro Kikuchi is an Professor in the Department of Surgery, Institute for Advanced Medical Science, Hyogo College of Medicine, Nishinomiy, Japan. His study interests major on biotechnology.
Publications
-
Review Article
Prospective Anticancer Therapy for CCL2-CCR2 Pathway Inhibition using Propagermanium
Author(s): Shojiro Kikuchi* and Takahito Jomori
Cancer stromal interactions have an essential role in the development and progression of most cancers. Cancer cells utilize the host's immune system for growth, invasion, survival, and metastasis. Because the CCL2 (chemokine (C-C-motif) ligand 2–CCR2 (C-C chemokine receptor type 2 pathway consists of a major inflammatory chemokine and receptor, various studies have been conducted to suppress cancer metastasis via this pathway. Many studies have indicated that the migration of tumor-associated macrophages (TAM) and monocytic bone marrow-derived suppressor cells (Mo-MDSCs) from the bone marrow into the microenvironment known as the "niche", which utilizes the CCL2–CCR2 pathway, promotes cancer metastasis. In line with this strategy, CCL2-neutralizing antibody CNTO888 (Carlumab), anti-CCR2 antibody (MLN1202, plozalizumab), and CCR2 antagonist (CCX872-.. View more»